Given that p53, the major transcriptional activator of p21, is the most frequently mutated gene in human cancer [44] and that hyperactive Cdk1 contributes to the development of different types of cancer [45], it is of clinical importance to study the function of p21 in cancer cells, its relevance in drug sensitivity and in tumor recurrence. This evidence concerns the gene CDKN1A and neoplasm.